Fabien Picard, Michele Pighi, Quentin de Hemptinne, Juhani Airaksinen, Giulia Vinco, Aurélien de Pommereau, Fausto Biancari, Olivier Varenne, Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents: A systematic review and meta-analysis, International Journal of Cardiology, Volume 278, 2019, Pages 51-56, ISSN 0167-5273, https://doi.org/10.1016/j.ijcard.2018.11.113
Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents : a systematic review and meta-analysis
|Author:||Picard, Fabien1,2; Pighi, Michele3; de Hemptinne, Quentin4;|
1Department of Cardiology, Hôpital Cochin, AP-HP, Paris, France
2Université Paris Descartes, Faculté de Médecine, Paris, France
3Department of Medicine, McGill University Health Center, Montréal, Canada
4Department of Cardiology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
5Heart Center, Turku University Hospital and University of Turku, Turku, Finland
6Department of Medicine, University of Verona, Verona, Italy
7Department of Surgery, University of Turku, Turku, Finland
8Department of Surgery, University of Oulu, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 0.8 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019102134086
|Publish Date:|| 2019-11-23
Aims: Despite similar efficacy and safety profile in pilot studies, bioresorbable polymer drug-eluting stents (BP-DES) could have potential benefit over latest generation durable polymer (DP)-DES by facilitating vessel healing, therefore reducing inflammation and neoatherosclerosis leading to enhanced clinical safety. Therefore, we sought to perform a meta-analysis of randomized clinical trials (RCTs) comparing the safety and efficacy of everolimus-eluting BP-DES (BP-EES) to second-generation DP-DES.
Methods and results: We conducted a systematic review and meta-analysis to examine the safety and efficacy of BP-EES in patients treated for coronary artery disease. We searched PubMed, Scopus, and the Cochrane Library through February 2018 for RCTs that included outcome data on BP-EES. We identified four eligible studies, which included a total of 4631 patients. Three studies reported a follow-up of one year and one study of five years. The BP-EES group, included 2315 patients and the DP-DES group included 2316 patients (1143 treated with DP-EES and 1173 treated with zotarolimus eluting DP-DES). Patient’s characteristics were comparable between the two groups except for higher prevalence of prior MI in the DP-DES group (25.7 vs 22.5%, respectively, p = 0.001). Procedural characteristics were comparable among groups except for slightly longer lesions in the BP-EES group compared to the DP-DES group (mean 15.1 vs 14.9 mm, p = 0.04). No significant differences were observed for cardiac mortality (p = 0.72), occurrence of MI (p = 0.64), any TLR (p = 0.93), ST (p = 0.85) or major adverse cardiac events (p = 0.43).
Conclusion: Overall, based on the available data BP-EES had similar one-year outcomes to contemporary DP-DES. Whether these devices could enhance clinical safety remains to be evaluated at longer follow-up.
International journal of cardiology
|Pages:||51 - 56|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3126 Surgery, anesthesiology, intensive care, radiology
© 2018 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.